FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:536-538 February 10, 2005 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by List, A. PubMed Citation

One of the most challenging problems in hematology is the heterogeneous group of disorders that were formally defined as myelodysplastic syndromes by the French–American–British Cooperative Group in 1982. This set of disorders includes idiopathic conditions as well as the secondary or therapy-related forms that develop after exposure to alkylating agents, radiation, or both. Idiopathic myelodysplastic syndromes occur mainly in older persons: the incidence of these syndromes is about 5 per 100,000 persons per year in the general population, but it increases to 20 to 50 per 100,000 persons per year after 60 years of age. Approximately 15,000 new cases are . . . [Full Text of this Article]

Source Information

Dr. Cazzola is a professor of hematology and Dr. Malcovati a senior fellow at the University of Pavia Medical School, Pavia, Italy. Dr. Cazzola is an attending physician at the Division of Hematology, Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.

Related Letters:

Treatment of Myelodysplastic Syndromes
Chng W. J., Stadler M., Ganser A., List A. F., Cazzola M., Malcovati L.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2134-2135, May 19, 2005. Correspondence

This article has been cited by other articles:

• Malcovati, L., Della Porta, M. G., Pietra, D., Boveri, E., Pellagatti, A., Galli, A., Travaglino, E., Brisci, A., Rumi, E., Passamonti, F., Invernizzi, R., Cremonesi, L., Boultwood, J., Wainscoat, J. S., Hellstrom-Lindberg, E., Cazzola, M. (2009). Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 114: 3538-3545 [Abstract] [Full Text]  
• Cazzola, M. (2009). Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. haematol 94: 1041-1043 [Full Text]  
• Ogata, K., Della Porta, M. G., Malcovati, L., Picone, C., Yokose, N., Matsuda, A., Yamashita, T., Tamura, H., Tsukada, J., Dan, K. (2009). Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. haematol 94: 1066-1074 [Abstract] [Full Text]  
• Howard, D. S., Pawlik, T. M. (2009). Withdrawing Medically Futile Treatment. J Oncol Pract 5: 193-195 [Full Text]  
• Porta, M. G. D., Malcovati, L. (2009). Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. haematol 94: 602-606 [Full Text]  
• Jabbour, E., Garcia-Manero, G., Taher, A., Kantarjian, H. M. (2009). Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. The Oncologist 14: 489-496 [Abstract] [Full Text]  
• Lyons, R. M., Cosgriff, T. M., Modi, S. S., Gersh, R. H., Hainsworth, J. D., Cohn, A. L., McIntyre, H. J., Fernando, I. J., Backstrom, J. T., Beach, C.L. (2009). Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes. JCO 27: 1850-1856 [Abstract] [Full Text]  
• Della Porta, M. G., Malcovati, L., Boveri, E., Travaglino, E., Pietra, D., Pascutto, C., Passamonti, F., Invernizzi, R., Castello, A., Magrini, U., Lazzarino, M., Cazzola, M. (2009). Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. JCO 27: 754-762 [Abstract] [Full Text]  
• Malcovati, L., Porta, M. G D., Laarakkers, C. M, Galli, A., Albertini, R., Maffioli, M., Ambaglio, I., Travaglino, E., Invernizzi, R., Moratti, R., Swinkels, D. W., Cazzola, M. (2008). Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome. ASH ANNUAL MEETING ABSTRACTS 112: 2676-2676 [Abstract]  
• Alessandrino, E. P., Della Porta, M. G., Bacigalupo, A., Van Lint, M. T., Falda, M., Onida, F., Bernardi, M., Iori, A. P., Rambaldi, A., Cerretti, R., Marenco, P., Pioltelli, P., Malcovati, L., Pascutto, C., Oneto, R., Fanin, R., Bosi, A. (2008). WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112: 895-902 [Abstract] [Full Text]  
• Jadersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., Hellstrom-Lindberg, E. (2008). Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome. JCO 26: 3607-3613 [Abstract] [Full Text]  
• Cazzola, M. (2008). Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. haematol 93: 967-972 [Full Text]  
• Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., Barrett, J. (2008). Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy. JCO 26: 2505-2511 [Abstract] [Full Text]  
• Nimer, S. D. (2008). Myelodysplastic syndromes. Blood 111: 4841-4851 [Abstract] [Full Text]  
• Malcovati, L., Cazzola, M. (2008). Myelodysplastic/myeloproliferative disorders. haematol 93: 4-6 [Full Text]  
• Cazzola, M., Della Porta, M. G., Malcovati, L. (2008). Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes. ASH Education Book 2008: 166-175 [Abstract] [Full Text]  
• Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., Strupp, C., Lazzarino, M., Aul, C., Cazzola, M. (2007). Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. JCO 25: 3503-3510 [Abstract] [Full Text]  
• Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., Pinto, A., Beran, M., de Witte, T. M., Stone, R. M., Mittelman, M., Sanz, G. F., Gore, S. D., Schiffer, C. A., Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425 [Abstract] [Full Text]  
• Schiller, G. J., Slack, J., Hainsworth, J. D., Mason, J., Saleh, M., Rizzieri, D., Douer, D., List, A. F. (2006). Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes. JCO 24: 2456-2464 [Abstract] [Full Text]  
• Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M., Cazzola, M. (2005). Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. JCO 23: 7594-7603 [Abstract] [Full Text]  
• Chng, W. J., Stadler, M., Ganser, A., List, A. F., Cazzola, M., Malcovati, L. (2005). Treatment of Myelodysplastic Syndromes. NEJM 352: 2134-2135 [Full Text]